Medical Devices; Neurological Devices; Classification of Repetitive Transcranial Magnetic Stimulation System

Health and Human Services Department; Food and Drug Administration · 2011

Read Medical Devices; Neurological Devices; Classification of Repetitive Transcranial Magnetic Stimulation System by Health and Human Services Department; Food and Drug Administration (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-18806.txt.

Description

Rule published in the Federal Register on 2011-07-26 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 44489-44491] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-18806] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 882 [Docket No. FDA-2011-N-0466] Medical Devices; Neurological Devices; Classification of Repetitive Transcranial Magnetic Stimulation System AGENCY: Food.

Catalog record

CREATORHealth and Human Services Department; Food and Drug Administration
YEAR2011
COLLECTIONLAW
FORMATTXT
FILE SIZE16 KB
VERSION1.0
LICENSEPublic Domain
RIGHTSPUBLIC DOMAIN
SOURCEFederal Register

Source: https://www.federalregister.gov/documents/2011/07/26/2011-18806/medical-devices-neurological-devices-classification-of-repetitive-transcranial-magnetic-stimulation

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Medical Devices; Neurological Devices; Classification of Repetitive Transcranial Magnetic Stimulation System Citation: us:fr:2011-18806 Creator: Health and Human Services Department; Food and Drug Administration Year: 2011 Source-URL: https://www.federalregister.gov/documents/2011/07/26/2011-18806/medical-devices-neurological-devices-classification-of-repetitive-transcranial-magnetic-stimulation Context: Rule published in the Federal Register on 2011-07-26 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 44489-44491] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-18806] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 882 [Docket No. FDA-2011-N-0466] Medical Devices; Neurological Devices; Classification of Repetitive Transcranial Magnetic Stimulation System AGENCY: Food and Drug Administration, HHS. ACTION: Final rule. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is classifying the repetitive transcranial magnetic stimulation (rTMS) system into class II (special controls). The Agency is classifying this device type into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of these devices. DATES: This final rule is effective August 25, 2011. FOR FURTHER INFORMATION CONTACT: Ann H. Costello, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, rm. 2460, Silver Spring, MD 20993-0002, 301- 796-6493. SUPPLEMENTARY INFORMATION: I. What is the background of this rulemaking? In accordance with section 513(f)(1) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 360c(f)(1)), devices that were not in commercial distribution before May 28, 1976, the date of enactment of the Medical Device Amendments of 1976, generally referred to as postamendments devices, are classified automatically by statute into class III without any FDA rulemaking process. These devices remain in class III and require premarket approval, unless the device is classified or reclassified into class I or class II, or FDA issues an order finding the device to be substantially equivalent, in accordance with section 513(i) of the FD&C Act (21 U.S.C. 360c(i)), to a predicate device that does not require premarket approval. The Agency determines whether new devices are substantially equivalent to predicate devices by means of premarket notification procedures in section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and part 807 of FDA's regulations (21 CFR part 807). Section 513(f)(2) of the FD&C Act provides that any person who submits a premarket notification under section 510(k) of the FD&C Act for a device that has not previously been classified may, within 30 days after receiving an order classifying the device in class III under section 513(f)(1), request FDA to classify the device under the criteria set forth in section 513(a)(1). FDA must, within 60 days of receiving such a request, classify the device by written order. This classification will be the initial classification of the device type. Within 30 days after the issuance of an order classifying the device, FDA must publish a notice in the Federal Register announcing this classification (section 513(f)(2) of the FD&C Act). In accordance with section 513(f)(1) of the FD&C Act, FDA issued an order on April 27, 2007, classifying the NeuroStar[reg] TMS System for the treatment of major depressive disorder in patients who have failed to receive benefit from one antidepressant trial into class III, because it was not substantially equivalent to a device that was introduced or delivered for introduction into interstate commerce for commercial distribution before May 28, 1976, or a device that was subsequently reclassified into class I or class II. On May 23, 2007, Neuronetics, Inc., submitted a petition requesting classification, under section 513(f)(2) of the FD&C Act, of the NeuroStar[reg] TMS System for the treatment of major depressive disorder in patients who have failed to receive benefit from one antidepressant trial. The manufacturer recommended that the device be classified into class II (Ref. 1). In accordance with section 513(f)(2) of the FD&C Act, FDA reviewed the petition in order to classify the device under the criteria for classification set forth in 513(a)(1) of the FD&C Act. FDA classifies devices into class II if general controls, by themselves, are insufficient to provide reasonable assurance of safety and effectiveness, but there is sufficient information to establish special controls to provide reasonable assurance of the safety and effectiveness of the device for its intended use. After review of the information submitted in the petition, FDA determined that the rTMS system can be classified into class II with the establishment of special controls. FDA believes that these special controls, in addition to general controls, are adequate to provide reasonable assurance of the safety and effectiveness of the device. Elsewhere in this issue of the Federal Register, FDA is announcing the availability of a guidance document entitled ``Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation System,'' which will serve as the special control for rTMS systems. The device is assigned the generic name ``Repetitive Transcranial Magnetic Stimulation System.'' A repetitive transcranial magnetic stimulation system is an external device that delivers transcranial repetitive pulsed magnetic fields of sufficient magnitude to induce neural action potentials in the prefrontal cortex to treat the symptoms of major depressive disorder without inducing seizure in patients who have failed at least one antidepressant medication and are currently not on any antidepressant therapy. FDA has identified the risks to health associated with this type of device as follows: Failure to identify correct patient population; Ineffective treatment; Seizure; Scalp discomfort, scalp burn, or other adverse effects; Magnetic field effects on functioning of other medical devices; Adverse tissue reaction; Hazards associated with electrical equipment; Hazards caused by electromagnetic interference and electrostatic discharge hazards; and Hearing loss. FDA believes that the class II special controls guidance document will aid in [[Page 44490]] mitigating the potential risks to health as described in table 1 of this document. Table 1--Risks to Health and Mitigation Measures ---------------------------------------------------------------------------------------------------------------- Identified risk Mitigation measures ---------------------------------------------------------------------------------------------------------------- Failure to identify correct patient Clinical testing. population. Labeling. Ineffective treatment.................... Nonclinical analysis and testing. Software life cycle and risk management. Clinical testing. Labeling. Seizure.................................. Nonclinical analysis and testing. Clinical testing. Labeling. Scalp discomfort, scalp burn, or other Nonclinical analysis and testing. adverse effects. Software life cycle and risk management. Clinical testing. Labeling. Magnetic field effects on functioning of Non-clinical analysis and testing. other medical devices. Labeling. Adverse tissue reaction.................. Biocompatibility. Hazards associated with electrical Electrical equipment safety. equipment. Labeling. Hazards caused by electromagnetic Electromagnetic compatibility. interference and electrostatic discharge hazards. Labeling. Hearing loss............................. Labeling. ---------------------------------------------------------------------------------------------------------------- FDA believes that the special controls, in addition to general controls, address the risks to health identified previously in this document and provide reasonable assurances of the safety and effectiveness of the device type. Thus, on October 7, 2008, FDA issued an order to the petitioner classifying the device into class II. FDA is codifying this classification by adding Sec. 882.5805. Following the effective date of the final classification rule, manufacturers will need to address the issues covered in the special controls guidance. However, the manufacturer need only show that its device meets the recommendations of the guidance or in some other way provides equivalent assurance of safety and effectiveness. Section 510(m) of the FD&C Act provides that FDA may exempt a class II device from the premarket notification requirement under section 510(k), if FDA determines that premarket notification is not necessary to provide reasonable

Read the complete text